Fibrous Dysplasia Market Information: By Diagnosis (X-Rays, CT Scans, MRI, Bone Scan, Biopsy), Treatment (Medication (Bisphosphonates, Intravenous Pamidronate), Surgical), End User (Hospitals & Clinics, Research Centers) - Global Forecast Till 2023

Market Scenario
Fibrous dysplasia is a rare and chronic bone disorder in which fibrous tissue develops in place of normal bone, weakens the affected bone, and deform or fracture it. As per reports from The Johns Hopkins University, the exact cause of fibrous dysplasia is unknown, but it is believed to be due to a chemical irregularity in a specific bone protein. This bone protein abnormality may arise due to a gene mutation present at birth, although it is not known to be an inherited disorder.

It often results in uneven growth of bones, pain, brittle bones, and bone deformity. In fibrous dysplasia, the most commonly affected bones includes femur (thighbone), tibia (shin bone), ribs, skull, facial bones, humerus (the bone of the upper arm), pelvis, vertebrae in the spine (less often).

The fibrous dysplasia market growth is majorly attributed to the increasing prevalence of the bone disorders. Moreover, some cases of fibrous dysplasia leads to cancer, which is likely to drive the market growth.

Currently, no cure is available for fibrous dysplasia. However, present treatment methods helps to prevent complications, such as recurrent bone fractures to help make the condition less severe.

According to reports from International Osteoporosis Foundation, Each year an estimated 1.5 million individuals suffer a fracture due to bone disease. The risk of a fracture increases with age and is more in women. Furthermore, globalization in healthcare has increased the market growth.

Established market players in the developed countries leads the globalization by pushing new products and services into developing countries and emerging economies.

However, high cost of the current treatment methods and lack of alternative methods for the treatment of fibrous dysplasia may slow the market growth during the forecast period.

The global fibrous dysplasia market is expected to grow at a CAGR of ~6.2 % during the forecast period 2017-2023.

Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and Universities
- Medical Research Laboratories
- Market Research and Consulting Service Providers
- Potential Investors

Figure: Global Fibrous Dysplasia Market, By Region Market Share, 2016 (%)
Segmentations

The global fibrous dysplasia market is segmented on the basis by diagnosis, by treatment, and by end user.

On the basis of diagnosis, it is segmented into X-rays, CT scans, MRI, bone scan, biopsy, and others.

On the basis of treatment, it is segmented into medications, surgical, and others. The medications is further segmented into bisphosphonates, intravenous (IV) pamidronate, calcitonin, raloxifene, and others

On the basis of the end user, it is segmented into hospitals & clinics, research centers, and others.

Regional Analysis

The Americas dominate the global fibrous dysplasia market owing to well-developed technology, increasing patient with bone disorders, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global fibrous dysplasia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period.

Asia Pacific is the fastest growing market owing to the presence of rapidly developing healthcare technology, increasing patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries such as India is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead to the use of advanced equipment, which, in turn, may increase the market growth of the fibrous dysplasia in the region.

On the other hand, the Middle East & Africa holds the least share of the global fibrous dysplasia market due to limited screening, ignorance of diseases, and poor access to treatment, especially, in African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.

Key Players

Some of key the players in the market are Novartis AG, Pfizer Inc, Amgen Inc, AVEO Pharmaceuticals Inc, Bayer AG, Bellicum Pharmaceuticals Inc, MediaPharma srl, Merck & Co., Inc, Merrimack Pharmaceuticals Inc, Oncolyis BioPharma Inc, United Therapeutics Corp and others.

Research Methodology
Contents:

Table of Content

1. Report Prologue

2. Market Introduction
   2.1 Definition
   2.2 Scope of the Study
   2.2.1 Research Objective
   2.2.2 Assumptions
   2.2.3 Limitations

3. Research Methodology
   3.1 Introduction
   3.2 Primary Research
   3.3 Secondary research
   3.4 Market Size Estimation

4. Market Dynamics
   4.1 Drivers
   4.2 Restrains
   4.3 Opportunities
   4.4 Challenges
   4.5 Macroeconomic Indicators
   4.6 Technology Trends & Assessment

5. Market Factor Analysis
   5.1 Porters Five Forces Analysis
      5.1.1 Bargaining Power of Suppliers
      5.1.2 Bargaining Power of Buyers
      5.1.3 Threat of New Entrants
      5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Fibrous Dysplasia Market, by Diagnosis
6.1 Introduction
6.2 X-rays
6.2.1 Market Estimates & Forecast, 2017-2023
6.3 MRI
6.3.1 Market Estimates & Forecast, 2017-2023
6.4 CT scans
6.4.1 Market Estimates & Forecast, 2017-2023
6.5 Biopsy
6.4.1 Market Estimates & Forecast, 2017-2023

7. Global Fibrous Dysplasia Market, by Treatment
7.1 Introduction
7.2 Surgery
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Medications
7.3.1 Market Estimates & Forecast, 2017-2023

8. Global Fibrous Dysplasia Market, by End User
8.1 Introduction
8.2 Hospitals & Clinics
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Research centers
8.3.1 Market Estimates & Forecast, 2017-2023

9. Global Fibrous Dysplasia Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K.
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

11 Company Profiles
11.1 Amgen Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Bellicum Pharmaceuticals Inc
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Novartis AG
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 AVEO Pharmaceuticals Inc.
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Bayer AG
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Merck & Co., Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Pfizer Inc.
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others

12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES
Table 1 Fibrous Dysplasia Industry Synopsis, 2017-2023
Table 2 Global Fibrous Dysplasia Market Estimates and Forecast, 2017-2023, (USD Million)
Table 3 Global Fibrous Dysplasia Market by Region, 2017-2023, (USD Million)
Table 4 Global Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 5 Global Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 6 Global Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
Table 7 North America Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 8 North America Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 9 North America Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
Table 10 U.S. Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 11 US Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 12 US Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
Table 13 Canada Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 14 Canada Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 15 Canada Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
Table 16 South America Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 17 South America Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 18 South America Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
Table 19 Europe Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 20 Europe Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 21 Europe Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
Table 22 Western Europe Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 23 Western Europe Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 24 Western Europe Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
Table 25 Eastern Europe Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 26 Eastern Europe Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 27 Eastern Europe Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
Table 28 Asia Pacific Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 29 Asia Pacific Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 30 Asia Pacific Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
Table 31 Middle East & Africa Fibrous Dysplasia Market by Diagnosis, 2017-2023, (USD Million)
Table 32 Middle East & Africa Fibrous Dysplasia Market by Treatment, 2017-2023, (USD Million)
Table 33 Middle East & Africa Fibrous Dysplasia Market by End Users, 2017-2023, (USD Million)
LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Fibrous Dysplasia Market
Figure 3 Segmentation Market Dynamics for Fibrous Dysplasia Market
Figure 4 Global Fibrous Dysplasia Market Share, by Diagnosis 2016
Figure 5 Global Fibrous Dysplasia Market Share, by Treatment 2016
Figure 6 Global Fibrous Dysplasia Market Share, by End Users, 2016
Figure 7 Global Fibrous Dysplasia Market Share, by Region, 2016
Figure 8 North America Fibrous Dysplasia Market Share, by Country, 2016
Figure 9 Europe Fibrous Dysplasia Market Share, by Country, 2016
Figure 10 Asia Pacific Fibrous Dysplasia Market Share, by Country, 2016
Figure 11 Middle East & Africa Fibrous Dysplasia Market Share, by Country, 2016
Figure 12 Global Fibrous Dysplasia Market: Company Share Analysis, 2016 (%)
Figure 13 Amgen Inc: Key Financials
Figure 14 Amgen Inc: Segmental Revenue
Figure 16 Amgen Inc: Geographical Revenue
Figure 17 Bellicum Pharmaceuticals Inc: Key Financials
Figure 18 Bellicum Pharmaceuticals Inc: Segmental Revenue
Figure 19 Bellicum Pharmaceuticals Inc: Geographical Revenue
Figure 20 Novartis AG: Key Financials
Figure 21 Novartis AG: Segmental Revenue
Figure 22 Novartis AG: Geographical Revenue
Figure 23 AVEO Pharmaceuticals Inc: Key Financials
Figure 24 AVEO Pharmaceuticals Inc: Segmental Revenue
Figure 25 AVEO Pharmaceuticals Inc: Geographical Revenue
Figure 26 Merck & Co., Inc: Key Financials
Figure 27 Merck & Co., Inc: Segmental Revenue
Figure 28 Merck & Co., Inc: Geographical Revenue
Figure 29 Bayer AG: Key Financials
Figure 30 Bayer AG: Segmental Revenue
Figure 31 Bayer AG: Geographical Revenue
Figure 32 Pfizer Inc: Key Financials
Figure 33 Pfizer Inc: Segmental Revenue
Figure 34 Pfizer Inc: Geographical Revenue